Zogenix Zohydro Launch Will Test FDA’s Balanced Approach On Opioid Pain Reviews
This article was originally published in RPM Report
Executive Summary
FDA approved Zogenix’ single-entity hydrocodone product following a negative advisory committee meeting, and is facing ongoing opposition as the drug’s launch begins. The agency argues the risk is consistent with other extended-release opioids – and abuse-deterrent technology is too new to require.
You may also be interested in...
A Fitting Farewell: Hamburg Earns Praise From Rep. Rogers In Final Approps Hearing
FDA Commissioner Margaret Hamburg and House Appropriations Chair Hal Rogers (R-KY) have had ups and downs over the years, but Rogers praised her and her legacy on prescription abuse.
Turning the Page on Zohydro? New Formulations, New Division Leadership Should Help FDA Move Forward in Opioids
The long-time head of FDA’s pain drug review group, Bob Rappaport, has retired after 20 years at FDA. The new acting Division Director is Sharon Hertz – suggesting continuity in the substance of reviews, but perhaps a symbolic change in moving beyond the controversy over Zohydro.
Turning the Page on Zohydro? New Formulations, New Division Leadership Should Help FDA Move Forward in Opioids
The long-time head of FDA’s pain drug review group, Bob Rappaport, has retired after 20 years at FDA. The new acting Division Director is Sharon Hertz – suggesting continuity in the substance of reviews, but perhaps a symbolic change in moving beyond the controversy over Zohydro.